Non-invasive diagnostic method to objectively measure olfaction and diagnose smell disorders by molecularly targeted fluorescent imaging agent.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
29 Nov 2022
29 Nov 2022
Historique:
pubmed:
10
12
2022
medline:
10
12
2022
entrez:
9
12
2022
Statut:
epublish
Résumé
The sense of smell (olfaction) is one of the most important senses for animals including humans. Despite significant advances in the understanding mechanism of olfaction, currently, there are no objective non-invasive methods that can identify loss of smell. Covid-19-related loss of smell has highlighted the need to develop methods that can identify loss of olfaction. Voltage-gated sodium channel 1.7 (Na
Identifiants
pubmed: 36482968
doi: 10.1101/2021.10.07.463532
pmc: PMC9727758
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIDCD NIH HHS
ID : K23 DC019678
Pays : United States
Déclaration de conflit d'intérêts
Disclosure of Potential Conflicts of Interest S.P. and T.R. are shareholders of Summit Biomedical Imaging, T.R. is now an executive of and shareholder in Novartis AG. J.G., P.D.S.F., G.K. and T.R. are co-inventors on a Tsp1a-related patent application. All other authors have no conflicts to declare.